"10.1371_journal.pone.0146783","plos one","2016-01-27T00:00:00Z","Jennifer Krupka; Frauke May; Thomas Weimer; Ingo Pragst; Christoph Kleinschnitz; Guido Stoll; Con Panousis; Gerhard Dickneite; Marc W Nolte","CSL Behring GmbH, Marburg, Germany; University of Würzburg, Department of Neurology, Würzburg, Germany; CSL Limited, Bio21 Institute, Parkville, Victoria, Australia","Conceived and designed the experiments: MWN IP GD. Performed the experiments: JK MWN. Analyzed the data: JK MWN FM. Contributed reagents/materials/analysis tools: TW. Wrote the paper: JK MWN FM TW IP CK GS CP GD. Provided expert advice: CK GS CP.","JK, FM, TW, IP and MWN are employees of CSL Behring GmbH. GD has been an employee of CSL Behring GmbH. CP is an employee of CSL Limited. GS has been a consultant of CSL Behring GmbH. CK receives financial support from CSL Behring GmbH to conduct research on FXII in experimental stroke. Furthermore, CSL Behring holds a patent/ patent application regarding the FXIIa inhibitor rHA-Infestin-4 and the respective use (Name: Therapeutic application of Kazal-type serine protease inhibitors; Number: WO 2008/1098720 A1). The commercial affiliation of authors JK, FM, TW, IP, MWN, GD and CP as well as CSL Behring GmbH holding the patent do not alter our adherence to PLOS ONE policies on sharing data and materials.","2016","01","Jennifer Krupka","JK",9,TRUE,3,2,3,9,TRUE,TRUE,FALSE,0,NA,FALSE
